Chemo-radiotherapy in non-small cell lung cancer: the role of gemcitabine.
Gemcitabine (2'-2'-difluorodeoxycytidine) is a well-known cytotoxic drug and a potent radio-enhancer. We herein report the in vitro evidence of its activity, and the clinical experiences when this drug is administered concurrently with radiation. The phase I-II trials are analyzed, focusing on the recent ability to deliver irradiation with low incidence of side effects.
Trodella
L
L
Radiotherapy Unit, University Campus Bio-Medico, Rome, Italy. l.trodella@unicampus.it
D'Angelillo
R M
RM
Ramella
S
S
Cellini
F
F
Ciresa
M
M
Cesario
A
A
Granone
P
P
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D020360:Neoadjuvant Therapy; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D000093542:Gemcitabine
D011838:Radiation-Sensitizing Agents; D003841:Deoxycytidine; D000093542:Gemcitabine